CN102250179A - Stable protein kinase activator, and preparation method and purpose thereof - Google Patents
Stable protein kinase activator, and preparation method and purpose thereof Download PDFInfo
- Publication number
- CN102250179A CN102250179A CN2011100099297A CN201110009929A CN102250179A CN 102250179 A CN102250179 A CN 102250179A CN 2011100099297 A CN2011100099297 A CN 2011100099297A CN 201110009929 A CN201110009929 A CN 201110009929A CN 102250179 A CN102250179 A CN 102250179A
- Authority
- CN
- China
- Prior art keywords
- camp
- hydrate
- salt
- protein kinase
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 18
- 108060006633 protein kinase Proteins 0.000 title claims abstract description 18
- 239000012190 activator Substances 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 17
- 206010019280 Heart failures Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 6
- 206010000830 Acute leukaemia Diseases 0.000 claims abstract description 5
- 208000009525 Myocarditis Diseases 0.000 claims abstract description 5
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000006454 hepatitis Diseases 0.000 claims abstract description 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 5
- 208000004124 rheumatic heart disease Diseases 0.000 claims abstract description 5
- 206010006451 bronchitis Diseases 0.000 claims abstract description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims abstract description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims abstract description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 42
- 238000003756 stirring Methods 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 25
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 150000004677 hydrates Chemical class 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 18
- 235000014852 L-arginine Nutrition 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 16
- HYMXALLEHXXORK-HTDNVCFESA-N (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 HYMXALLEHXXORK-HTDNVCFESA-N 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 14
- 150000007530 organic bases Chemical class 0.000 claims description 14
- 238000001291 vacuum drying Methods 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930195722 L-methionine Natural products 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 8
- 229960002173 citrulline Drugs 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 8
- 230000008014 freezing Effects 0.000 claims description 8
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 6
- 229930028154 D-arginine Natural products 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- 229960003194 meglumine Drugs 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000013477 citrulline Nutrition 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 206010007625 cardiogenic shock Diseases 0.000 claims description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
- 230000001788 irregular Effects 0.000 claims description 4
- 230000001185 psoriatic effect Effects 0.000 claims description 4
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 3
- 229930182818 D-methionine Natural products 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052797 bismuth Inorganic materials 0.000 claims description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229940110377 dl- arginine Drugs 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract description 3
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 239000004475 Arginine Substances 0.000 description 19
- 235000009697 arginine Nutrition 0.000 description 19
- 229960003121 arginine Drugs 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 238000012856 packing Methods 0.000 description 14
- -1 salt anhydride Chemical class 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- 239000012982 microporous membrane Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 238000002329 infrared spectrum Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 238000001757 thermogravimetry curve Methods 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 159000000003 magnesium salts Chemical class 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 4
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 3
- 238000005262 decarbonization Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229960001462 sodium cyclamate Drugs 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229940075509 carbomer 1342 Drugs 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- PPNKDDZCLDMRHS-UHFFFAOYSA-N dinitrooxybismuthanyl nitrate Chemical compound [Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PPNKDDZCLDMRHS-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000002333 Asphyxia Neonatorum Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010049765 Bradyarrhythmia Diseases 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000021944 Butyrylcholinesterase Human genes 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010056467 Cerebral dysgenesis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- OHTWNYYNKQVOSM-UHFFFAOYSA-N O.[Cl].[Na] Chemical compound O.[Cl].[Na] OHTWNYYNKQVOSM-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical compound NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-N dithionous acid Chemical compound OS(=O)S(O)=O GRWZHXKQBITJKP-UHFFFAOYSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 229940026231 erythorbate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940114123 ferulate Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008359 glycogelatin Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- KWUZCAVKPCRJPO-UHFFFAOYSA-N n-ethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(NCC)=CC=C1C1=NC2=CC=C(C)C=C2S1 KWUZCAVKPCRJPO-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- BXJBFCKTIWRKMQ-MGLVZFEGSA-M sodium;(4ar,6r,7as)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1C(O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 BXJBFCKTIWRKMQ-MGLVZFEGSA-M 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- OGWLTJRQYVEDMR-UHFFFAOYSA-F tetramagnesium;tetracarbonate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O OGWLTJRQYVEDMR-UHFFFAOYSA-F 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a novel stable protein kinase activator adenosine cyclophosphate derivative, which has good storage stability and preparation performance and can be applied to preparations of medicaments for treating or preventing human and mammal diseases, such as angina pectoris, heart failure, myocardial infarction, myocarditis, arrhythmia, acute leukemia, neurological diseases, respiratory system disease, senile chronic bronchitis, hepatitis and psoriasis, etc, and medicaments for improving symptoms of palpitaition, dyspnea and chest distress of rheumatic heart disease.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of hydrate and preparation and purposes of stable protein kinase activator-cAMP salt.
Background technology
CAMP is the protein kinase activator, is the derivative of Nucleotide.It is a kind of important substance with physiologically active that extensively exists in human body, is generated under adenosine cyclase catalysis by Triphosaden, can regulate the multiple functional activity of cell.The 2nd courier as hormone, performance hormone regulation physiological function and substance metabolism effect in cell, can change function of plasma membrane, impel the calcium ion in the sarcoplasm matter to enter myofiber, thereby enhancing myocardial contraction, and can promote the oxidasic activity of respiratory chain, and improve myocardial anoxia, alleviate coronary heart disease symptom and improve electrocardiogram(ECG.In addition, sugar, metabolism of fat, nucleic acid, proteinic synthetic adjusting etc. are played an important role.
Present disclosed document has only been reported some salt of cAMP and purposes, as be used for the treatment of stenocardia, heart failure, myocardial infarction, myocarditis, irregular pulse and cardiogenic shock, improve the palpitaition of rheumatic heart disease, symptom, acute leukemia, nervous system disorders, respiratory system disease, hepatitis and psoriatic etc. such as out of breath, uncomfortable in chest.[reference: the clinical efficacy research of cAMP treatment chronic heart failure acute exacerbation phase, Hebei medical science, 2004,10(7): p627; CAMP to mitral valve replacement after the influence of myocardial enzymes, Chinese Journal of New Drugs 2002,10 (7): p559-561; Cyclic AMP injecta treatment congestive heart failure, Kaifeng doctor special journal 2000,19 (3): p13; Dobutamine associating cAMP treatment clinical observation in heart failure, contemporary Chinese medicinal application, 2010,16:p132-133; The pharmacological action of meglumine cyclic adenylate and clinical application, Chinese medicine company, 1999,8(5): p31; Chinese Pharmaceutical Journal, 1992,27 (6): p371; Anti-arrhythmic effects of meglumine cyclic adenylate, Chinese J Pharmacol Toxicol, 1989,3 (4): p251-254; The cardiovascular magazine of China, 1999,4 (5): p283; Meglumine Cyclic Adenylate is to bradyarrhythmia and observation of curative effect in heart failure, clinical department of internal medicine magazine 2004,21 (8): p574; Cardiac damage curative effect after the meglumine cAMP treatment asphyxia neonatorum, paediatrics pharmaceutical journal 2001,7 (3): p18; Meglumine Adenosine Cyelophosphate is inquired into the therapeutic action and the mechanism of childhood asthma, China's medicine in the present age, 2010,17 (3): p49-50; TVI observes the influence of meglumine cyclic adenylate to mitral annular motion, shanghai Medicine image 2004,13 (4): p251-252; Meglumine Adenosine Cyelophosphate is to the influence of chronic heart failure patient heart function and Type B natriuretic peptide, and Chinese medicine is innovated, and 2009,34(6): p13-14].
But the hydrate and its production and use of protein kinase activator-cAMP salt that up to the present, does not still have both at home and abroad the new stable of open source literature report.
Summary of the invention
One of purpose of the present invention provides a kind of hydrate of stablizing, being difficult for drawing wet cAMP salt.
The hydrate of 3 ', 5 '-cyclic monophosphate salt provided by the invention (Adenosine Cyclophosphate), its molecular formula is { [cAMP]
mAnH
2O, cAMP are C
10H
12N
5O
6P or C
10H
11N
5O
6P, m=1~3, n=0.88~8.5}, m=1 or 2 or 3, n can be 0.88,1,1.25,1.5,2,2.5,3.0,3.5,4,5,6,7,8,8.5 or the numeral between it.
A is selected from a kind of of pharmaceutically acceptable metal ion or organic bases.Wherein organic bases comprises triethylamine, diethylamine, thanomin, meglumine, Portugal's ethamine, Trometamol, a kind of in piperazine, morpholine, L-Methionin, D-Methionin, DL-Methionin, L-arginine, D-arginine, DL-arginine, Histidine, ornithine, the citrulline etc., amino acid includes the amino acid (D or L type amino acid) of racemization and chirality, and metal ion is a kind of in lithium, potassium, sodium, calcium, magnesium, zinc, aluminium or the bismuth.
The salt of the cAMP that contains crystal water that the present invention obtains is different from the characteristic that cAMP is insoluble in water, surprisingly, the salt that does not contain the cAMP of crystal water draws moist salt far above the cAMP that contains crystal water, contain crystal water cAMP salt hydrate than do not contain crystal water more can be stable existence, be convenient to store and transportation, some of them salt at room temperature has good water-solubility, is easy to make water miscible preparation.Distinctive, the weightless as can be seen platform of the heat analysis of hydrate of the present invention (TG-DSC or TG-DTA) collection of illustrative plates has the endotherm(ic)peak of intensive correspondence, and the thermogram spectrum demonstrates cAMP L-arginine 1 hydrate (C
10H
12N
5O
6PC
6H
14N
4O
2H
2O), cAMP L-Methionin 1 hydrate (C
10H
12N
5O
6PC
6H
14N
2O
2H
2O), cAMP DL-Methionin 1 hydrate, meglumine cyclic adenylate 1 hydrate (C
10H
12N
5O
6PC
7H
17NO
5H
2O), cAMP sodium 2 hydrate (C
10H
11N
5O
6PNa2H
2O), cAMP magnesium salts 8 hydrate [(C
10H
11N
5O
6P)
2Mg8H
2O], cAMP calcium salt 3.5 hydrate [(C
10H
11N
5O
6P)
2Ca3.5H
2O] etc., measuring its moisture with the karl Fischer method, its result is consistent with hot analytical results.
The present invention also comprises cAMP D-arginine 1 hydrate, cAMP D-Methionin 1 hydrate, cAMP DL-Methionin 1 hydrate, cAMP L-citrulline 1 hydrate, cAMP triethylamine 1 hydrate, cAMP diethylamine 1 hydrate etc.
The hydrate of the salt of cAMP of the present invention can stable storage.With the salt anhydride sample of the hydrate of the salt of above-mentioned cAMP and cAMP airtight respectively with cillin bottle in carry out accelerated stability test (chromatographic condition: chromatographic column: C
L8(250mm * 4.6mm, 5 μ m); Moving phase: 0.05mol/L potassium dihydrogen phosphate (including the 0.01mol/L Tetrabutyl amonium bromide)-acetonitrile (85:15); Flow velocity: lml/min; Temperature: room temperature; Detect wavelength: 259nm), unexpectedly find, the content of the hydrate of the salt of cAMP of the present invention and related substance change less, the salt anhydride accelerated test of cAMP 6 months was compared (40 ℃ with 0 month, RH75%), the multiple of related substance increase is higher than the hydrate of the salt of cAMP.Draw moist test by the Chinese Pharmacopoeia requirement: get the salt anhydride and the about 5g of hydrate of the present invention of cAMP, place the watch-glass of dry constant weight, precision is weighed.25 ℃, relative humidity are 75%, respectively at test 0h and 48h sampling, calculate the percentage that draws wet weightening finish, the result shows, anhydride draws moist more much higher than hydrate of the present invention, illustrates that the hydrate of the salt of cAMP of the present invention has better storage stability.The results are shown in Table 1~6, the hydrate of each the cAMP salt among the table 1-6 is all by corresponding embodiment method preparation.
In addition, the deliquescence of anhydride makes wants secluding air to prevent adhesion etc. when handling, and does not have good sliding like hydrate, improves the operability of preparation.
CAMP is a protein kinase activator.It is a kind of important substance with physiologically active that extensively exists in human body, is generated under adenosine cyclase catalysis by Triphosaden, can regulate the multiple functional activity of cell.Second messenger as hormone, performance hormone regulation physiological function and substance metabolism effect in cell, can change function of plasma membrane, impel the calcium ion in the net agonistic muscle slurry matter to enter myofiber, thereby enhancing myocardial contraction, and can promote the oxidasic activity of respiratory chain, and improve myocardial anoxia, alleviate coronary heart disease symptom and improve electrocardiogram(ECG.In addition, sugar, metabolism of fat, nucleic acid, proteinic synthetic adjusting etc. are played an important role.
In the derivative of cAMP of the present invention except that the cAMP that contains protein kinase activator, also contain important basic metal and alkaline-earth metal ions or amino acid etc., these ions or amino acid have different physiological roles, for example: magnesium is the major element of needed by human, magnesium ion has the various biological activity, be to keep the normal neural muscle excitability and the requisite factor of histocyte energy metabolism, magnesium ion is that important cofactor is being brought into play important physiological function in the interior plurality of enzymes system of organism in the human body metabolic processes.It mainly acts on as follows:
1, keeps the activity of enzyme
Magnesium is cofactor or the agonist that many enzymes are, can start 300 plurality of enzymes in the body, comprises hexokinase, Na
+-K
+ATP enzyme, carboxylase, pyruvic oxidase, peptase, Pseudocholinesterase etc., participate in many important metabolic processes in the body, comprise the metabolism of protein, fat and carbohydrate and nucleic acid, oxidative phosphorylation, ion transport, the generation of nerve impulse and transmission, Muscle contraction etc., almost relevant with each link of vital movement.
2, keep the excitability of excitable cell
Magnesium ion all plays restraining effect to central nervous system, neuromuscular and cardiac muscle etc.For nervomuscular irritability, Mg
2+With Ca
2+Working in coordination with, is again antagonism for cardiac muscle.
3, keep the genetic stability of cell
Magnesium is main cofactor and decision cell cycle and the interior attemperator of apoptotic cells in the DNA related enzyme systems.
At present, contain the magnesium medicine and have vital role at step-down, cholagogic, catharsis, aspect such as anticonvulsion, merge heart failure at treatment asthma, capillary bronchitis, severe pneumonia, exhale decline, brain declines and respiratory system disease such as pulmonary hypertension in brought into play spasmolysis, relievingd asthma, calm, many-sided comprehensive action such as eliminate the phlegm, and in experimentation on animals and a large amount of clinical practice, obtained confirmation.
Calcium ion is the indispensable ion of the every physiological activity of body.It keeps normal nerve conduction function for the biopotential of keeping the cytolemma both sides.Keep normal muscle flexible and diastolic function and nerve-muscle conduction function, also have some functions of hormones mechanism all to show by calcium ion.Main effect or mechanism are:
1, calcium ion is a thrombin, participates in coagulation process.
2, participate in muscle (comprising skeletal muscle, unstriated muscle) contraction process, impel heartbeat.
3, participate in neurotransmitter synthetic with release, hormone is synthetic and secretion, and conduction nerve signal.Its transmission mechanism is for promoting neurotransmitter secretion.When the body calcium deficiency, the release of neurotransmitter is intercepted, and the excitation mechanism of human body and inhibition mechanism are destroyed.If children's calcium deficiency, can the morbid night crying of babies, sleep terror fright at night, irritated insomnia, the serious brain development obstacle that causes, occurs slow in reacting, move more, disease such as difficulty of learning, influence brain maturation and intelligence.
4, be the important substance that bone constitutes.
5, transmit the signal of resisting the enemy.Its mechanism is: when exotic antigen activated T cell acceptor, started the signal path of calcium ion mediation, impelled immunocyte differentiation and growth.In case function of immune system decline, disorder will take place in calcium deficiency, and be diseases induced.As: autoimmune disorder lupus erythematosus, rheumatosis; Tetter: dermatitis, acne etc.Replenish the calcium, play an important role treating these diseases.
Arginine is the necessary amino acid of a kind of condition, participates in the tricarboxylic acid cycle in the energy metabolism in vivo and has the ornithine cycle of detoxification, impels the human body energy balance, can reduce blood ammonia after the medication, promotes that toxic substance excretes, and reaches the purpose of Ginseng Extract.Its pharmacological action is extensive, and it has mainly acted on:
(arginine Arg) is the nitric oxide production source of human body to arginine, and nitrogen protoxide (NO) impels vasorelaxation, stimulates circulation.Arginine can promote the recovery of heart rate; increase volume of blood flow coronarius, improve heart function, cardiac muscle is had the certain protection effect; the normal blood supply function of heart when prompting replenishes arginine and helps to protect motion is to the generation of delay fatigue with promote to recover tool and have certain effect.The inferior maximal exercise result of experiment that the myocardial ischemia patient replenishes behind the L-arginine shows that arginine supplementation group coronary artery blood flow when exercise testing is clearly better.The L-arginine replenishes can obviously improve the motor capacity of the spastic patient with angina pectoris of coronary artery, and has persistence preferably, and plasma nitric oxide levels is significantly improved.
Studies show that, arginine can effectively reduce the incidence of myocardial infarction, have vasodilator, hypotensive, the effect of stimulating circulation smoothly simultaneously, prevention and arteriosclerotic for cardiovascular disorder, the incidence of myocardial infarction has tangible reduction effect, and arginine also has antioxygenation, can reduce low-density lipoprotein (LDL) oxidation, form the sedimentary effect of blood vessel inner layer chyle, therefore for the little angiemphraxis of heart, cause the probability of myocardial necrosis to descend.
In addition, arginine has the specific immunity promoter action.Arginine and meta-bolites thereof such as nitrogen protoxide (NO) etc. are in immune defense, immunomodulatory, keep and protect the aspects such as specific immunity of intestinal mucosa function and tumour bringing into play important effect.
Arginine can effectively improve immunizing power, promote endogenous materials such as immunity system secretion natural killer cell, phagocytic cell, interleukin-11, help resisting cancer cells and prophylaxis of viral infections.No matter be normal diet or vein input arginine, all can specificity strengthen the cellular immune function of normal or wound animal; In wound and tumor-bearing animal, except that alleviating the immunosuppression that wound causes, arginine can also strengthen lymphocyte function, and has potential IL-2 immunity antitumor action, can promote the T cell mitogen, improves nitrogen equilibrium, improves the animal survival rate, strengthen time-delay reaction hypersensitive.In addition, arginine is the precursors of ornithine and proline(Pro), and proline(Pro) is the important element that constitutes collagen protein, replenishes arginine and need organize the health of maintenance to protect in a large number for severe trauma, burn etc., have tangible help, have the effect that reduces infection and inflammation simultaneously.
Methionin belongs to basic aminoacids, is that human body one of must 8 seed amino acids, and Methionin provides structural constituent for synthetic carnitine, and carnitine can impel the synthetic of lipid acid in the cell.Particularly, higher to the requirement of Methionin in childhood development phase, decubation, pregnant lactication phase after being ill.Because content is lower in foods such as rice, corn, cause human body to lack easily, be called as " first lack amino acid ".
The Methionin shortage can cause dysplasia, loses the appetite, loses weight, negative nitrogen balance, hypoproteinemia, anaemia, enzymic activity descend and other physiological function obstacle.Methionin has the intelligence of raising, promotes growth, builds up health; Improve a poor appetite, improve malnutritive situation; Improve insomnia, memory; Help to produce antibody, hormone and enzyme, improve immunizing power, increase hemochrome; Help the absorption of calcium, treatment prevents osteoporosis; The help nervous tissue is repaired, and promotes nervous cell regenerating, improves the effect of central nervous tissue function.Methionin can improve blood-brain barrier permeability; help medicine to enter in the brain cell; clinical cerebral protective agent as treatment craniocerebral trauma, chronic brain tissue ischemia, anoxic disease; or, also can be used for Methionin and lack children's's poor appetite, malnutrition and the cerebral dysgenesis that causes the assisting therapy of other encephalopathics.The imidazolyl energy and the Fe of Histidine
2+Or other metal ions formation coordination compoundes, promote the absorption of iron, thereby can be used for preventing and treating anaemia.Histidine can reduce gastric acidity, relaxes the pain of gastro-intestinal surgery, alleviates Gestation period vomiting and stomach burning sensation, suppresses nervous by vegetative nerve and digestive tube that cause festers, and is to anaphylactic disease, also powerful as asthma etc.In addition, the expansible blood vessel of Histidine brings high blood pressure down, and is used for treatment of diseases such as stenocardia, cardiac insufficiency clinically.Histidine content significantly reduces in the patient with rheumatoid arthritis blood, uses and to find its grip behind the Histidine, walks and index such as erythrocyte sedimentation rate all take a favorable turn.
The L-citrulline can improve function of immune system, safeguards the joint motion function, balance euglycemia level, absorb harmful free radical, help to keep the cholesterol normal level, improve the health function, the pulmonary function of maintaining healthy improves mental sharpness, reduces pressure and overcomes dejected mood.Citrulline can be in human body and the ammonia effect, generates arginine and nitrogen protoxide and makes vasodilator, and be used for the treatment of spirit and physical fatigue and sexual dysfunction.Citrulline belongs to amino acid drug, can same ornithine, arginine etc. share in the treatment hyperammonemia.Citrulline can absorb in the blood fully, produces nitrogen protoxide, participates in diversified physiological process, as killing and erection etc. of neurotransmission, antiotasis, sphincter dilatation, microorganism, male's sexual is had extremely important effect.Nitrogen protoxide is in the presence of oxygen molecule and oxyphorase, forms when becoming the L-citrulline by nitric oxide synthetase (NOS) catalysis L-arginine guanidine radicals oxidative deamination.
Contain pharmaceutically acceptable metal ion or organic bases in the The compounds of this invention, metal ion comprises alkalimetal ion or alkaline-earth metal ions etc., organic bases comprises amino acid, triethylamine, diethylamine, thanomin etc., wherein amino acid includes the amino acid (D or L type amino acid) of racemization and chirality, and form stable compound, make it in the prevention of various disease or treatment, have more advantage, perhaps make when other derivative of preparation cAMP more convenient than single cAMP.
The present invention also provide described cAMP salt hydrate the preparation method and be used for stenocardia, heart failure, myocardial infarction, myocarditis, irregular pulse and cardiogenic shock, improve the purposes of the palpitaition of rheumatic heart disease, disease prevention such as symptom, acute leukemia, nervous system disorders, respiratory system disease, hepatitis and psoriatic such as out of breath, uncomfortable in chest or treatment.
The hydrate preparation method of the salt of cAMP comprises:
Method A. is in reaction vessel, add water and cAMP, stir, add oxide compound or oxyhydroxide or its metal-salt or its solution of pharmaceutically acceptable organic bases or metal by the mol ratio of reaction, stir, question response finishes, and filters, and slowly adds the lower ketones of C3-C7, as acetone, or the low mass molecule alcohol of C1-C6, as methyl alcohol, ethanol, Virahol, one or more in the rudimentary ether of C2-C8, cooling, filter, solids is with the low mass molecule alcohol of organic solvent C1-C6, as methyl alcohol, ethanol, Virahol, the lower ketones of C3-C7, as acetone, rudimentary ether such as the ether of C2-C6, or one or more rinses in the water, drain, drying obtains the hydrate of cAMP salt;
Perhaps method B. puts into the oxide compound of metal or the solution of oxyhydroxide or its metal-salt or organic bases in the reaction vessel that contains cAMP and water by the mol ratio of reaction, stir, between 0~50 ℃ of the controlled temperature, stir, question response finishes, activated carbon decolorizing, one or many filters, and it is freezing to-70~-30 ℃, heats up, vacuum-drying must have the hydrate of cAMP salt;
Perhaps method C. will contain the oxide compound of metal or a kind of or its solution of oxyhydroxide or its metal-salt or pharmaceutically acceptable organic bases in the reaction vessel of cAMP and water by the mol ratio adding of reacting respectively, stir, between the controlled temperature-5~40 ℃, reaction 0.5~24h, question response finishes, activated carbon decolorizing, and one or many filters, spraying drying, the hydrate of cAMP salt.In the spraying drying, inlet temperature can be between 100 ~ 140 ℃, and air outlet temperature can be between 70 ~ 100 ℃, and spray is pressed can be at 1.0 ~ 2.0kg/cm
2
Within 60~120 ℃, generally within 90~120 ℃, Vanadium Pentoxide in FLAKES is a siccative with the hydrate of the salt of cAMP, and high vacuum dry 8 hours is to more than a few days, the salt anhydride of cAMP.And the comparison that the product of gained can be used to draw moist test or accelerated stability test.
Lower ketones among the present invention or low molecule ketone are defined as C3-C7, as acetone, and butanone etc.; Lower alcohol or low mass molecule alcohol are defined as C1-C6, and as methyl alcohol, ethanol, Virahol, rudimentary ether or low molecule ether are defined as C2-C8, as ether, butyl ether etc.The oxide compound of the metal of mentioning or oxyhydroxide or its metal-salt, can be respectively: calcium oxide, calcium hydroxide, magnesium oxide, magnesium basic carbonate, sodium hydroxide, yellow soda ash, sodium bicarbonate, zinc oxide, aluminium sesquioxide, potassium hydroxide, salt of wormwood, Bismuth trinitrate, its metal-salt comprise carbonate or supercarbonate or subcarbonate.
The hydrate purposes of the salt of cAMP of the present invention: the hydrate of the salt of cAMP of the present invention is used to prepare injection freeze-dried powder or great transfusion preparation or little water needle injection, aseptic subpackaged powder pin, solid preparation, comprise tablet, capsule, granule, comprise ointment, gelifying agent etc. through preparation for external application to skin.
Be used to prepare tablet, capsule or the granule of solid preparation, can contain pharmaceutically acceptable weighting agent in these preparations, as starch, modified starch, lactose, Microcrystalline Cellulose, cyclodextrin, sorbyl alcohol, N.F,USP MANNITOL, calcium phosphate, amino acid etc.; Pharmaceutically acceptable disintegrating agent is as starch, modified starch, Microcrystalline Cellulose, sodium starch glycolate, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, tensio-active agent; Pharmaceutically acceptable wetting agent and tackiness agent are as gelling starch, methylcellulose gum, Xylo-Mucine, ethyl cellulose, polyvinylpyrrolidone, Lalgine and salt thereof; Pharmaceutically acceptable lubricant and glidant are as stearic acid, Magnesium Stearate, Macrogol 4000-8000, talcum powder, micropowder silica gel, Stepanol MG etc.; Pharmaceutically acceptable sweeting agent and essence are as aspartame, Sodium Cyclamate, soluble saccharin, Sucralose, food flavour etc.
The deliquescence that crystalline hydrate of the present invention is different from anhydride makes wants secluding air to prevent adhesion etc. when handling, and crystalline hydrate has good sliding, thereby improves the operability of preparation; And the solid preparation that makes preparation has good dissolving out capability, makes it be absorbed easily and enters blood circulation, improves bioavailability, and helps bringing into play fast its effect.From another aspect, making it prevent produces obstruction and makes loading amount generation difference cause underdosage when carrying out being difficult for when aseptic subpackaged to cause packing because of the moisture absorption, thereby bring the defective of product, or because underproof product is not inspected by random samples the actual omission of formation, and then come into the market, in clinical treatment,, perhaps jeopardize patient's life because of underdosage to patient's the negative effect of treatment agency.Perhaps when packing, cause whole production line to be forced to suspend because of the moisture absorption, seriously reduce the throughput of equipment, increase the hidden danger of work time cost etc. greatly.The hydrate of cAMP salt of the present invention with respect to anhydride between the shelf lives related substance be that the content increasing degree of impurity is lower than hydrate, preparation for the intravenously administrable for the treatment of cardiovascular and cerebrovascular diseases will help improving the security of clinical administration greatly.
Because the cAMP micro dissolution is in water, need to add the auxiliary material of oil soluble generally speaking, be easy to pollute, and difficult the cleaning, the storage stability of the hydrate of the salt of cAMP of the present invention and the general easy characteristic that is dissolved in water make in the ease for operation that has more preparation aspect the preparation gelifying agent, its prepared gelifying agent has good release performance, make it be absorbed easily and enter blood circulation, improve bioavailability, and help bringing into play fast its effect.Need not to add the auxiliary material of oil soluble, be difficult for polluting, and than easy cleaning.
The preparing gel of the hydrate of cAMP salt: with cAMP salt hydrate and 50~95% matrix mixings, matrix can be ethanol, glycerine, trolamine, glycogelatin, Macrogol 200~8000, poloxamer, polyvinylpyrrolidone, semi-synthetic hard fatty acids fat, water-soluble mono-glycerides, carbomer series (931,934,940,974, AA-1,1342 etc.), polysorbate60-80.Can contain pharmaceutically receivable sanitas and stablizer in the gel, can be during preparation respectively with the carbomer water-dispersion, add glycerine, Macrogol 200~8000, heating, mix, add the cAMP salt hydrate, stirring of recipe quantity, with pharmaceutically receivable mineral alkali or organic bases are regulated about pH=5.0~8.5, add water to full dose, be stirred to even, packing, promptly.
The hydrate injection of the salt of cAMP, its preparation method is:
The aseptic subpackaged powder injection of the hydrate of the salt of cAMP can prepare according to ordinary method.
The preparation method of freeze-dried powder is: get the hydrate of the salt of cAMP, can add pharmaceutically acceptable frozen-dried supporting agent or auxiliary shape agent, add injection and blunge and make dissolving, if need, available pharmaceutically acceptable acid-alkali accommodation pH is 4.0~8.5, adds activated carbon 0.005~0.5%(W/V) and stirs 15~45min, filters, moisturizing, sterile filtration is by 20~200mg/bottle (in cAMP) packing, lyophilize, tamponade gets finished product.
The hydrate injection with small volume and the preparation technology thereof of the salt of cAMP: the hydrate of the salt of cAMP adds injection water and pharmaceutically acceptable additives, for example: pharmaceutically acceptable pH regulator agent, pharmaceutically acceptable oxidation inhibitor, rare gas element, the sterilization injection with small volume is made in filtration, degerming, and its pH value is between 4.0~8.5.
Its pharmaceutically acceptable pH regulator agent can be pharmaceutically acceptable mineral acid or organic acid, mineral alkali or organic bases, also can be generalized Lewis acid or alkali, can contain one or several, can be hydrochloric acid, phosphoric acid, propionic acid, acetic acid and acetate, as sodium-acetate etc., lactic acid and lactic acid pharmaceutical salts, the Citric Acid pharmaceutical salts, yellow soda ash, sodium bicarbonate, saleratus, sodium hydroxide, potassium hydroxide, phosphoric acid salt, tartrate and pharmaceutical salts thereof, borax, boric acid, Succinic Acid, caproic acid, hexanodioic acid, FUMARIC ACID TECH GRADE, maleic acid, the trihydroxy-aminomethane, diethanolamine, thanomin, Yi Bingchunan, diisopropanolamine (DIPA), 2-amino-2-(methylol) 1, ammediol amine, 1, the 2-hexanediamine, N-methyl grape amine, Diisopropylamine and their salt, multi-hydroxy carboxy acid and pharmaceutical salts are as glucuronic acid, gluconic acid, lactobionic acid, oxysuccinic acid, threonic acid, glucoheptonic acid, in amino acid and the amino acid salts etc. one or several.
Its pharmaceutically acceptable oxidation inhibitor and stablizer can be sulfurous acid, sulphite, hydrosulphite, pyrosulfite, hyposulfite, thiosulphate, organosulfur compound thiocarbamide, gsh, dimercaprol dimercaptopropanol, Thiovanic acid and salt, thiolactic acid and salt, thio-2 acid and salt, phenol compound, as gallic acid and salt, coffic acid, caffeiate, forulic acid, ferulate, di-t-butyl Pyrogentisinic Acid, 2,5-resorcylic acid, 2,5-resorcylic acid salt, Whitfield's ointment or its salt; Amino acid with and salt; Xitix and ascorbate salt, saccharosonic acid and erythorbate, niacinamide, tartrate, nitrate, phosphoric acid salt, acetic acid pharmaceutical salts, Citrate trianion, EDTA and edta salt, as in EDTA disodium, EDTA four sodium etc. one or several.
Its pharmaceutically acceptable isotonic regulator can be one or more in glucose, fructose, Xylitol, sorbyl alcohol, N.F,USP MANNITOL, Nulomoline, maltose, dextran, sodium-chlor, Repone K, the Sodium.alpha.-hydroxypropionate etc.
Source and the degerming mode of reducing phlegm and internal heat can be the gac that adds dosing amount 0.005~3% source of reducing phlegm and internal heat, and millipore filtration degerming and pressure sterilizing also can adopt heat sterilization, the source of reducing phlegm and internal heat.In the hyperfiltration process, that ultra-fine filter can be selected for use is flat, rolling, tubular type, tubular fibre formula or circle boxlike etc., preferred rolling and tubular fibre formula ultra-fine filter, it is after 50,000 to 300,000 filter membrane is removed most of heat generation material and bacterium that relative molecular mass is held back in employing, adopt the ultra-filtration membrane of holding back relative molecular mass 3000~30000 to remove the residue thermal source, the ultra-filtration membrane of preferred relative molecular mass 6000~20000 again.
The hydrate of the salt of cAMP of the present invention, be applicable to the application in the medicine of following treatment that caused humans and animals is infected of preparation or prevention: be used for stenocardia, heart failure, myocardial infarction, myocarditis, irregular pulse and cardiogenic shock in preparation, improve the application in the medicine of treatment such as the palpitaition of rheumatic heart disease, symptom, acute leukemia, nervous system disorders, respiratory system disease, senile chronic bronchitis, hepatitis and psoriatic such as out of breath, uncomfortable in chest or prevention.
Consumption usage: generally speaking,, get medicine 0.020~0.2g of the present invention in 0.9% sodium-chlor or 5~10% glucose, 20~500 milliliters, do intravenous injection or instillation, every day 1~2 time in the adult; Get medicine 0.020~0.2g of the present invention and be dissolved in the water for injection, intramuscularly, every day 1~2 time; Children's amount of reducing by half is above to be used.
Through gastrointestinal administration consumption usage: the human or animal of 10~70 kg body weight, 40~600mg/ days generally speaking, divide 2-3 administration; Children's amount of reducing by half is above to be used.Topical administration, directly Tu is in the affected part, once a day to six times.
Description of drawings
Fig. 1 is the thermogram spectrum of magnesium salts 8 hydrates of cAMP.
Fig. 2 is the thermogram spectrum of meglumine cyclic adenylate salt 1 hydrate.
Fig. 3 is the thermogram spectrum of cAMP L-arginic acid salt 1 hydrate.
Fig. 4 is the thermogram spectrum of cAMP L-lysine salt 1 hydrate.
Fig. 5 is the thermogram spectrum of cAMP sodium salt 2 hydrates.
Fig. 6 is the X ray diffracting spectrum of magnesium salts 8 hydrates of cAMP.
Embodiment
The invention discloses a kind of hydrate and preparation and purposes of cAMP salt, those skilled in the art can use for reference this paper content, suitably improve processing parameter and realize.Special needs to be pointed out is that all similarly replace and change apparent to those skilled in the art, they all are regarded as being included in the present invention.Product of the present invention, method and application are described by preferred embodiment, the related personnel obviously can change or suitably change and combination methods and applications as herein described in not breaking away from content of the present invention, spirit and scope, realizes and use the technology of the present invention.
In specific embodiment, hot analytical test condition is: the Setsys of Setaram company 16, PE-6300TGDTA, the about 5mg of sample size, heat-up rate: 10K/min, N
2Flow velocity: 50ml/min, room temperature~400 ℃.
X-ray diffractogram is to utilize D/MX-III A X-ray diffractometer at Wuhan University of Technology testing of materials center, and diffraction angle 2 θ, have measured the x-ray diffractogram of powder of hydrate of the present invention by sweep limit 3-60 °.
In one embodiment, utilize powder X-ray diffractometry to measure, in diffraction angle 2 θ (3-60 °) useful range, magnesium salts 8 hydrates of cAMP of the present invention can have corresponding eigenwert in the position that comprises following 2 θ values: about 4.3,5.9,11.0,13.0,16.9,17.9,20.0,21.6,24.3,26.0,31.3,33.9.
In one embodiment, utilize powder X-ray diffractometry to measure, in diffraction angle 2 θ (3-60 °) useful range, meglumine cyclic adenylate 1 hydrate of the present invention can have corresponding eigenwert in the position that comprises following 2 θ values: about 6.3,15.0,17.9,20.8,22.5.
In one embodiment, utilize powder X-ray diffractometry to measure, in diffraction angle 2 θ (3-60 °) useful range, cAMP L-arginine 1 hydrate of the present invention can have corresponding eigenwert in the position that comprises following 2 θ values: about 3.5,17.6,20.8,30.2,34.5.
In one embodiment, utilize powder X-ray diffractometry to measure, in diffraction angle 2 θ (3-60 °) useful range, cAMP L-Methionin 1 hydrate of the present invention can have corresponding eigenwert in the position that comprises following 2 θ values: about 14.2,15.8,17.6,20.7,27.0.
In specific embodiments, cAMP salt hydrate of the present invention is carried out check and analysis, wherein the assay of cAMP carries out with reference to the China national drug standard.
In one embodiment, cAMP salt hydrate of the present invention is carried out check and analysis, wherein arginic assay (HPLC method) and discriminating can be with reference to Chinese Pharmacopoeia versions in 2005, and the method for P588 arginine hydrochloride sheet is carried out.
In one embodiment, cAMP salt hydrate of the present invention carrying out check and analysis, wherein the mensuration reference literature of Methionin: agricultural brightness etc. lysine hydrochloride and Injection by HPLC thereof are measured, chemical industry technology and exploitation, 2003,32 (2): 33.
In order to make those skilled in the art understand technical scheme of the present invention better, the present invention is described in further detail below in conjunction with specific embodiment.
The preparation of magnesium salts 8 hydrates of embodiment 1 cAMP
In the 250ml three-necked flask, add cAMP 0.1mol, water 100ml, stir, the magnesium oxide that adds 0.05mol, 20~60 ℃ were stirred about 50 minutes down, made dissolving, filtered, the acetone that adds 5 times of amounts is separated out solid, be cooled to about-10 ℃, placed 24 hours, filter, about 50 ℃ dryings of solids got off-white color solid 23.6g in 4 hours, fusing point: 227 ℃ of decomposition (not proofreading and correct), HPLC: cAMP content 39.86%, it is 17.57% that the Ka Shi method is measured moisture, heat is analyzed: the weightless about 17.16%(of platform sees accompanying drawing 1), this and sample contain result's (theoretical value 17.48%) of 8 crystal water in limit of error; Infrared spectra: ν
KBr MaxCm
-13437,3210,2913,2428,1659,1606,1581,1488,1425,1384,1343,1290,1237,1136,1095,1053,1022,952,869,843,724,640,545; Ultimate analysis theoretical value: C 29.12%, H4.64%, N16.98% P7.51%, Mg 2.95%; Measured value: C 29.33%, H4.52%, N17.11% P7.67%, Mg 3.23%.
The preparation of embodiment 2 cAMP calcium salts 3.5 hydrates
In the 250ml three-necked flask, add the cAMP 0.1mol after pure, water 100ml, stir, the calcium hydroxide or the calcium oxide that add 0.05mol, 20~60 ℃ were stirred about 60 minutes down, make dissolving, filter, add the dehydrated alcohol and the Virahol (1:1) of 5 times of amounts, be cooled to-10~5 ℃, placed 24 hours, treat that solid separates out, filter, dry 4~6 hours dryings about 50 ℃, get off-white color solid 19.2 grams, fusing point: 223 ℃ of decomposition (ELECTROTHERMAL MELTING POINT APPARATUS does not proofread and correct), infrared spectra: it is 8.52% that the Ka Shi method is measured moisture, heat is analyzed: platform is weightless about 8.4%, and this and sample contain result's (theoretical value 8.30%) of 3.5 crystal water in limit of error; ESI:m/z:328; Infrared spectra: ν
KBr MaxCm
-13436,3209,2913,2428,1658,1606,1581,1488,1425,1384,1343,1290,1237,1136,1094,1053,1022,951,869,843,724,640,545; Ultimate analysis theoretical value: C 31.63%, H3.85%, N18.44% P8.16%, Ca 5.28%; Measured value: C 31.57%, H3.94%, N18.36% P8.07%, Ca 5.35%.
The preparation of embodiment 3 meglumine cyclic adenylates 1 hydrate
With the cAMP 10g after pure and and equimolar meglumine drop in the reaction flask, add water 200ml, stir, between 10~60 ℃ of the controlled temperature, reaction 10~120min, the centesimal gac that adds the solution total amount stirs half an hour and filters, use 0.22 micron filtering with microporous membrane again, it is freezing to-60~-40 ℃, keeps about 4 hours, is warming up to then about-16 ℃, between the vacuum tightness 5-12Pa, about vacuum-drying 20 hours, again at 20~30 ℃, between the vacuum tightness 5-12Pa, vacuum-drying is about 4 hours, get the off-white color solid, this solid is soluble in water, fusing point: 67~71. ℃ (ELECTROTHERMAL MELTING POINT APPARATUS does not proofread and correct); HPLC: cAMP content is 60.79%, ESI:m/z:523,328,19,6,195; Moisture (Ka Shi method): 3.51%, heat is analyzed: platform is weightless about 3.31%, and result's (theoretical value 3.32%) that this and sample contain 1 crystal water (sees accompanying drawing 3) in limit of error; Infrared spectra: ν
KBr MaxCm
-13404,3210,2918,2766,2427,1648,1605,1571,1478,1422,1384,1332,1299,1233,1134,1083,1018,945,839,765,724,644,540; Ultimate analysis theoretical value: C 37.64%, H5.76%, N15.49% P5.71%; Measured value: C 37.52%, H5.87%, N15.37% P5.56%.
The preparation of embodiment 4 cAMP L-arginine 1 hydrate
With the cAMP 10g after pure and and equimolar L-arginine drop in the reaction flask, add water 200ml, stir, between 10~60 ℃ of the controlled temperature, reaction 10~120min, the centesimal gac that adds the solution total amount stirs half an hour and filters, and uses 0.22 micron filtering with microporous membrane again, and it is freezing to-60~-40 ℃, kept about 4 hours, be warming up to then about-16 ℃, under the vacuum tightness 0.5-15Pa, vacuum-drying is about 20 hours, again at 20~30 ℃, between the vacuum tightness 0.5-15Pa, about vacuum-drying 4-8 hour, get off-white color solid 10.1g, this solid is soluble in water, fusing point: 189~195 ℃ of (ELECTROTHERMAL MELTING POINT APPARATUS, do not proofread and correct), HPLC: cAMP content is 63.07%, arginine 33.31%; ESI:m/z:502,328,175,158; It is 3.82% that the Ka Shi method is measured moisture, and heat is analyzed: the weightless about 3.61%(of platform sees accompanying drawing 4), this and sample contain result's (theoretical value 3.46%) of 1 crystal water in limit of error; Infrared spectra: ν
KBr MaxCm
-13422,3210,2928,2765,2426,2071,1641,1476,1384,1331,1238,1134,1083,1018,839,796,765,72,3,643,540; Ultimate analysis theoretical value: C 36.86%, H5.41%, N24.18%, P5.94%; Measured value: C 37.08%, H5.20%, N24.36%, P5.75%.
The preparation of embodiment 5 cAMP L-Methionins 1 hydrate
With the cAMP 10g after pure and and equimolar L-Methionin drop in the reaction flask, add water 220ml, stir, between 10~60 ℃ of the controlled temperature, stirring reaction 30min, the centesimal gac that adds the solution total amount stirs half an hour and filters, use 0.22 micron filtering with microporous membrane again, it is freezing to-60~-40 ℃, keeps about 4 hours, is warming up to then about-20 ℃, under vacuum tightness 0.8-15Pa, about vacuum-drying 20 hours, again at 20~30 ℃, under the vacuum tightness 0.8-15Pa, vacuum-drying is about 4 hours, get off-white color solid 11.6g, this solid is soluble in water, fusing point: 195~201 ℃ of decomposition (ELECTROTHERMAL MELTING POINT APPARATUS does not proofread and correct); HPLC: cAMP content is 66.65%, Methionin 29.46%; ESI:m/z:474,328,147,130; Moisture (Ka Shi method): 3.96%, heat is analyzed: the weightless about 4.01%(of platform sees accompanying drawing 5), this and sample contain result's (theoretical value 3.65%) of 1 crystal water in limit of error; Infrared spectra: ν
KBr MaxCm
-13424,3198,2933,2766,2427,1642,1599,1509,1477,1384,1332,1237,1134,1083,1018,839,796,7,59,724,644,542.
Embodiment 6 is with the preparation of cAMP sodium 2 hydrates
10g places reaction flask with cAMP, add water 200ml, stir, slowly in reaction flask, add and the equimolar sodium bicarbonate of cAMP, stir, between 10~60 ℃ of the controlled temperature, reaction 30min, the gac that adds solution gross weight 0.2% stirs half an hour and filters, and uses 0.22 micron filtering with microporous membrane again, it is freezing to-70~-40 ℃, be warming up to then about-16 ℃, between the vacuum tightness 0.5-10Pa, vacuum-drying is about 20 hours, again at 20~30 ℃, between the vacuum tightness 2-12Pa, about vacuum-drying 6 hours, get off-white color solid 10.6g, this solid is soluble in water, fusing point: 227 ℃ of decomposition (ELECTROTHERMAL MELTING POINT APPARATUS does not proofread and correct); Assay: HPLC method: cAMP content is 84.82%; Moisture (Ka Shi method): 9.47%, heat is analyzed: the weightless about 9.03%(of platform sees accompanying drawing 6), this and sample contain result's (theoretical value 9.31%) of 2 crystal water in limit of error; ESI:m/z:350; Ultimate analysis theoretical value: C 31.02%, H3.90%, N18.09%, P8.00%, Na5.94%; Measured value: C 30.88%, H4.03%, N18.19%, P8.12%, Na5.83%.
The preparation of embodiment 7 cAMP DL-Methionins 1 hydrate
With the cAMP 10g after pure and and equimolar DL-Methionin drop in the reaction flask, add water 220ml, stir, between 10~60 ℃ of the controlled temperature, reaction 10~120min, the centesimal gac that adds the solution total amount stirs half an hour and filters, hold back the ultrafiltration membrance filter of relative molecular mass 6000~30000 again with 0.22 micron filtering with microporous membrane or employing, it is freezing to-70~-30 ℃, keeps about 24 hours, is warming up to then about-16 ℃, under the vacuum tightness 2-10Pa, about vacuum-drying 20 hours, again at 20~30 ℃, between the vacuum tightness 2-10Pa, vacuum-drying is about 6 hours, get off-white color solid 12.2g, this solid is soluble in water, fusing point: 194~199 ℃ of decomposition (ELECTROTHERMAL MELTING POINT APPARATUS does not proofread and correct); HPLC: cAMP content is 66.52%, Methionin 29.34%; ESI:m/z:474,330,328,147,130; Moisture (Ka Shi method): 4.02%, heat is analyzed: platform is weightless about 3.83%, and this and sample contain result's (theoretical value 3.65%) of 1 crystal water in limit of error; Infrared spectra: ν
KBr MaxCm
-13424,3198,2933,2766,2427,1642,1599,1509,1477,1384,1332,1237,1134,1083,1018,839,796,7,59,724,644,542.
The preparation of embodiment 8 cAMP D-arginine 1 hydrate
With the cAMP 10g after pure and and equimolar D-arginine drop in the reaction flask, add water 200ml, stir, between 10~60 ℃ of the controlled temperature, reaction 10~120min, the centesimal gac that adds the solution total amount stirs half an hour and filters, and uses 0.22 micron filtering with microporous membrane again, and it is freezing to-70~-40 ℃, kept about 5 hours, be warming up to then about-16 ℃, under the vacuum tightness 3-15Pa, vacuum-drying is about 20 hours, again at 20~30 ℃, between the vacuum tightness 3-15Pa, about vacuum-drying 6 hours, get off-white color solid 11.5g, soluble in water, fusing point: 190~194 ℃ of (ELECTROTHERMAL MELTING POINT APPARATUS, do not proofread and correct), HPLC: cAMP content is 63.01%, arginine 33.35%; It is 3.78% that the Ka Shi method is measured moisture, and heat is analyzed: platform is weightless about 3.57%, and this and sample contain result's (theoretical value 3.46%) of 1 crystal water in limit of error.
The preparation of embodiment 9 cAMP triethylamines 1 hydrate
With reference to the method for embodiment 3, be prepared into cAMP triethylamine 1 hydrate of off-white color.
CAMP L-arginine 1 hydrate or cAMP L-Methionin 1 hydrate or cAMP DL-Methionin 1 hydrate or meglumine cyclic adenylate 1 hydrate 200g are got in the preparation (each hydrate of cAMP prepares by corresponding embodiment method) of embodiment 10 cAMP L-arginine 1 hydrates or cAMP L-Methionin 1 hydrate or cAMP DL-Methionin 1 hydrate or meglumine cyclic adenylate 1 hydrate freeze-dried preparation, adding glucose or N.F,USP MANNITOL or Xylitol 2.0~5g adds fresh water for injection 10~20L and stirs and make dissolving, an amount of with 2M hydrochloric acid or 2M sodium hydroxide, regulating pH is 5.0~8.5, add activated carbon 0.01~0.5%(W/V) and stir 15~45min, filter, hold back the ultrafiltration membrance filter of relative molecular mass 6000~20000 with 0.22 micron filtering with microporous membrane or employing, press 20mg, 30mg/ bottle or 40mg or 50mg/ bottle or 60mg/ bottle or 100mg/ bottle or 120mg/ bottle packing (in cAMP) packing, lyophilize, tamponade gets finished product.
CAMP L-arginine 1 hydrate (by the preparation of embodiment 4 methods) is got in the preparation of embodiment 11 freeze-dried preparation or meglumine cyclic adenylate 1 hydrate 10g(prepares by embodiment 3 methods) (in cAMP), with N.F,USP MANNITOL 40g, add 40~60 ℃ of water for injection 1460~1850ml stirrings and make dissolving, Citric Acid or sodium hydroxide adjusting pH with 1M are 5.0~8.0, add activated carbon 0.01~0.5%(W/V) and stir 15~45min, filter, moisturizing is to 2000ml, hold back the ultrafiltration membrance filter of relative molecular mass 6000~20000 with 0.22 micron filtering with microporous membrane or employing, by 20,30mg/ bottle or 60mg/ bottle or 100mg/ or 120mg/ bottle (by cAMP) packing, lyophilize, tamponade gets finished product.
Embodiment 12 gets the hydrate 20Kg(of salt of aseptic cAMP in cAMP) (each hydrate of cAMP is by corresponding embodiment method preparation), with aseptic subpackaged technology by 20,30mg/ bottle or 50mg/ bottle or 60mg/ bottle or the packing of 100mg/ bottle, jump a queue, tamponade, roll aluminium lid and get finished product.
Preparation cAMP sodium 2 hydrates of the small-volume injection of the hydrate of the salt of embodiment 13 cAMPs (by the preparation of embodiment 6 methods) or cAMP L-arginine 1 hydrate (by the preparation of embodiment 4 methods) or meglumine cyclic adenylate 1 hydrate (by the preparation of embodiment 3 methods) (by cAMP) 10 g, add cysteine hydrochloride 0.8g, EDTA disodium 0.1g, adding injection blunges and makes dissolving, it is 5.0~7.8 that 2M lactic acid and Sodium.alpha.-hydroxypropionate are regulated pH, add activated carbon 0.5%(W/V) stirring 15~45min, filter, moisturizing is to 1000ml, hold back the ultrafiltration membrance filter of relative molecular mass 6000~20000 with 0.22 micron filtering with microporous membrane or employing, by the packing of 2~10ml/ bottle, sterilize finished product.
The freeze-dried preparation preparation of embodiment 14 cAMP sodium 2 hydrates is got cAMP sodium 2 hydrate 10g(by the preparation of embodiment 4 methods), adding injection blunges and makes dissolving, add activated carbon 0.3%(W/V) stirring 15~45min, filter, moisturizing is to 2000ml, with 0.22 micron filtering with microporous membrane, by the packing of 2~5ml/ bottle, lyophilize, tamponade gets finished product.
The preparation of embodiment 15 cAMP sodium, 2 hydrates or cAMP L-arginine 1 hydrate or meglumine cyclic adenylate 1 hydrate high-capacity injection (hydrate of each cAMP salt is by corresponding embodiment method preparation)
Take by weighing glucose 500g and add in the water for injection, stir and make dissolving fully, add the gac of dosing amount 0.05%, heated about 10~30 minutes, put cold, filtering decarbonization; With hydrate (in the cAMP) 4.01g of the salt of cAMP with fresh water for injection dissolving fully after, mix with above-mentioned filtrate, add hydrochloric acid L-halfcystine 1g, EDTA disodium 0.2g, regulate the pH value in 5.2~7.5 scope with the 1M lactic acid solution, add the injection water to 10000ml, the gac that adds dosing amount 0.01~0.5%(W/V), about heated and stirred 10~30 minutes, filtering decarbonization, filter or adopt the ultrafiltration membrance filter of holding back relative molecular mass 6000~20000 through 0.22um millipore filtration essence again,, treat its content through the work in-process chemical examination, after pH value and clarity are qualified, embedding is in the vial of 50ml or 100ml or 200ml, sterilization, finished product inspection, packing is promptly.
The preparation of the hydrate sodium-chlor transfusion of the salt of embodiment 16 cAMPs
Hydrate (in cAMP) (hydrate of each cAMP salt is by corresponding embodiment method preparation) 4g with the salt of cAMP, sodium-chlor 85g, Sodium Pyrosulfite 1.1g, EDTA disodium 0.2g, add in the water for injection, stirring makes dissolving fully, Citric Acid and liquor sodii citratis with 1M are regulated the pH value in 4.0~7.5 scope, add the injection water to 10000ml, the gac that adds dosing amount 0.05%, about heated and stirred 10~30 minutes, filtering decarbonization, filter or adopt the ultrafiltration membrance filter of holding back relative molecular mass 6000~20000 through 0.22um millipore filtration essence again, chemically examine through work in-process, treat its content, after pH value and clarity were qualified, embedding was sterilized in the vial of 50ml or 100ml or 200ml, finished product inspection, packing promptly.
The preparation (the 250mg/ sheet is in cAMP) of embodiment 17. cAMP magnesium, 8 hydrates or cAMP L-arginine 1 hydrate tablet
Prescription: cAMP magnesium 8 hydrates or cAMP L-arginine 1 hydrate 250g(are in cAMP)
Microcrystalline Cellulose 200g
Sodium starch glycolate 20g
Aspartame 2g
Polyvinylpyrrolidone 5% is an amount of
Magnesium Stearate 2g
The capsular preparation of hydrate (the 100mg/ grain is in cAMP) of embodiment 18 cAMP salt
Prescription: the salt hydrate 100g(of cAMP is in cAMP)
Microcrystalline Cellulose 100g
Lactose 20g
Magnesium Stearate 2g
Hydrate (hydrate of each cAMP salt prepares by corresponding embodiment method), Microcrystalline Cellulose, the lactose of cAMP salt of the present invention are crossed 100 mesh sieves, gelling starch with 10% is made softwood in right amount, crossing the 18-24 mesh sieve granulates, dry, after crossing the whole grain of 14-20 mesh sieve, add Magnesium Stearate and mix the can capsule.
The preparation of the hydrate particle of embodiment 19 cAMP salt comprises cAMP sodium 2 hydrates or cAMP magnesium 8 hydrates or meglumine cyclic adenylate 1 hydrate or particles such as cAMP L-arginine 1 hydrate or cAMP L-Methionin 1 hydrate (the 50mg/ bag is in cAMP)
Prescription: the hydrate 50g(of cAMP salt is in cAMP)
N.F,USP MANNITOL 180g
Sucrose 20g
Sodium Cyclamate 2g
Solid food flavour 1g
Polyvinylpyrrolidone 5% is an amount of
Hydrate (hydrate of cAMP salt prepares by corresponding embodiment method), N.F,USP MANNITOL, sucrose, Sodium Cyclamate, the food flavour of cAMP salt are crossed 100 mesh sieves, polyvinylpyrrolidone with 5% is made softwood in right amount, crossing the 18-24 mesh sieve granulates, dry below 60 ℃, after crossing the whole grain of 14-20 mesh sieve, divide packing.
The gel of the hydrate of embodiment 20 cAMP salt of the present invention (hydrate of cAMP salt is by corresponding embodiment method preparation)
Prescription: the hydrate 25g(of cAMP salt feeds intake in cAMP)
Polyethylene glycol 6000 50g
Poly(oxyethylene glycol) 400 10g
Glycerine 5ml
Carbomer 934 8g
Carbomer 1342 2g
Water 400-500ml
Will be respectively with carbomer 1342 and carbomer 934 water-dispersion, add glycerine, polyethylene glycol 6000, poly(oxyethylene glycol) 400, mix, the hydrate that adds cAMP salt, heating, be stirred to even, regulate about pH=5.0~7.0 with Sodium phosphate dibasic and sodium dihydrogen phosphate, packing is promptly.
The variation that is appreciated that a lot of details is possible, and therefore this do not limit the scope of the invention and spirit, and the present invention is not limited to the foregoing description.
Claims (10)
1. a protein kinase activator is characterized in that, molecular formula is [cAMP]
mAnH
2O, cAMP are C
10H
12N
5O
6P or C
10H
11N
5O
6P, m=1 or 2 or 3, n=0.88~8.5, A is selected from a kind of of pharmaceutically acceptable metal ion or organic bases.
2. protein kinase activator according to claim 1, it is characterized in that: described organic bases is selected from triethylamine, diethylamine, thanomin, meglumine, Portugal's ethamine, Trometamol, a kind of in piperazine, morpholine, L-Methionin, D-Methionin, DL-Methionin, L-arginine, D-arginine, DL-arginine, Histidine, ornithine, the citrulline.
3. protein kinase activator according to claim 1 is characterized in that: described metal ion is selected from a kind of in lithium, potassium, sodium, calcium, magnesium, zinc, aluminium or the bismuth.
4. protein kinase activator according to claim 1 is characterized in that, it is cAMP L-arginine 1 hydrate or cAMP D-arginine 1 hydrate.
5. protein kinase activator according to claim 1 is characterized in that: it is cAMP L-Methionin 1 hydrate or cAMP DL-Methionin 1 hydrate.
6. protein kinase activator according to claim 1 is characterized in that: it is meglumine cyclic adenylate 1 hydrate.
7. stable protein kinase activator according to claim 1 is characterized in that: it is cAMP sodium 2 hydrates or cAMP calcium 3.5 hydrates or cAMP magnesium 8 hydrates.
8. protein kinase activator according to claim 1 is characterized in that: its preparation method is selected from following method:
Method A. mixes water and cAMP, the oxide compound or oxyhydroxide or its metal-salt or its solution that add pharmaceutically acceptable organic bases or metal by the mol ratio of reaction, stir, question response finishes, filter, the lower ketones that slowly adds C3-C6, or C1-C6 low mass molecule alcohol, one or more of the rudimentary ether of C2-C6, cooling, filter the solids low mass molecule alcohol of organic solvent C1-C6, the lower ketones of C3-C6, one or more rinses in the rudimentary ether of C2-C6 or the water, filter, drying obtains the hydrate of cAMP salt;
Perhaps method B. puts into the oxide compound of metal or the solution of oxyhydroxide or its metal-salt or organic bases in the reaction vessel that contains cAMP and water by the mol ratio of reaction, stir, between 0~50 ℃ of the controlled temperature, stir, question response finishes, activated carbon decolorizing, one or many filters, it is freezing to-70~-30 ℃, and vacuum-drying must have the hydrate of cAMP salt;
Perhaps method C. will contain the oxide compound of metal or a kind of or its solution of oxyhydroxide or its metal-salt or organic bases in the reaction vessel of cAMP and water by the mol ratio adding of reacting respectively, stir, between the controlled temperature-5~40 ℃, reaction 0.5~24h, question response finishes, activated carbon decolorizing, and one or many filters, spraying drying, the hydrate of cAMP salt.
9. be the injection freeze-dried powder of activeconstituents or aseptic subpackaged powder injection or little water needle injection or great transfusion preparation, solid preparation with the described protein kinase activator of claim 1, comprise tablet, capsule, granule, comprise ointment, gelifying agent through preparation for external application to skin.
10. the described protein kinase activator of claim 1 is applicable to following people of causing and mammalian diseases in preparation, comprise stenocardia, heart failure, myocardial infarction, myocarditis, irregular pulse and cardiogenic shock, improve the application in the medicine of the treatment of the palpitaition of rheumatic heart disease, symptom, acute leukemia, nervous system disorders, respiratory system disease, senile chronic bronchitis, hepatitis and psoriatic etc. such as out of breath, uncomfortable in chest or prevention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110009929.7A CN102250179B (en) | 2010-01-18 | 2011-01-18 | Stable protein kinase activator, and preparation method and purpose thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010029032A CN101781348A (en) | 2010-01-18 | 2010-01-18 | Stable protein kinase activator, preparation method thereof and use |
CN201010029032.6 | 2010-01-18 | ||
CN201110009929.7A CN102250179B (en) | 2010-01-18 | 2011-01-18 | Stable protein kinase activator, and preparation method and purpose thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102250179A true CN102250179A (en) | 2011-11-23 |
CN102250179B CN102250179B (en) | 2014-10-01 |
Family
ID=42521510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010029032A Pending CN101781348A (en) | 2010-01-18 | 2010-01-18 | Stable protein kinase activator, preparation method thereof and use |
CN201110009929.7A Expired - Fee Related CN102250179B (en) | 2010-01-18 | 2011-01-18 | Stable protein kinase activator, and preparation method and purpose thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010029032A Pending CN101781348A (en) | 2010-01-18 | 2010-01-18 | Stable protein kinase activator, preparation method thereof and use |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN101781348A (en) |
WO (1) | WO2011085701A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101781348A (en) * | 2010-01-18 | 2010-07-21 | 刘力 | Stable protein kinase activator, preparation method thereof and use |
CN102989034B (en) * | 2011-09-10 | 2016-01-20 | 温州医学院 | A kind of hydrogel being applied to nerve anastomosis and preparation method thereof |
CN105147569B (en) * | 2015-10-16 | 2018-01-19 | 广州丽彦妆生物科技有限公司 | A kind of antioxidant composition and temperature sensitive hydrogel for cosmetics |
CN106565796A (en) * | 2016-11-04 | 2017-04-19 | 南京工业大学 | Crystal of cyclic adenosine monophosphate sodium salt solvate and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49116096A (en) * | 1972-07-25 | 1974-11-06 | ||
JPH09116096A (en) * | 1995-10-16 | 1997-05-02 | Rohm Co Ltd | Semiconductor integrated circuit |
CN1931180A (en) * | 2006-05-25 | 2007-03-21 | 武汉安士医药科技有限公司 | Medicines of different characters and their prepn and use |
CN1948329A (en) * | 2006-11-09 | 2007-04-18 | 常月梅 | Technology of extracting adenosin phosphoric acid from date |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579413A (en) * | 2004-02-11 | 2005-02-16 | 江卫世 | Meglumine adenosine cyclophosphate for injection and its preparing method |
CN101172112A (en) * | 2007-05-25 | 2008-05-07 | 武汉安士医药科技有限公司 | Compound with special property, composition containing the compound, preparing method and uses of the same |
CN101781348A (en) * | 2010-01-18 | 2010-07-21 | 刘力 | Stable protein kinase activator, preparation method thereof and use |
-
2010
- 2010-01-18 CN CN201010029032A patent/CN101781348A/en active Pending
-
2011
- 2011-01-18 CN CN201110009929.7A patent/CN102250179B/en not_active Expired - Fee Related
- 2011-01-18 WO PCT/CN2011/070355 patent/WO2011085701A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49116096A (en) * | 1972-07-25 | 1974-11-06 | ||
JPH09116096A (en) * | 1995-10-16 | 1997-05-02 | Rohm Co Ltd | Semiconductor integrated circuit |
CN1931180A (en) * | 2006-05-25 | 2007-03-21 | 武汉安士医药科技有限公司 | Medicines of different characters and their prepn and use |
CN1948329A (en) * | 2006-11-09 | 2007-04-18 | 常月梅 | Technology of extracting adenosin phosphoric acid from date |
Non-Patent Citations (1)
Title |
---|
贾力,等: "葡甲胺环腺苷酸的抗心律失常作用", 《中国药理学与毒理学杂志》, vol. 3, no. 4, 30 November 1989 (1989-11-30), pages 251 - 253 * |
Also Published As
Publication number | Publication date |
---|---|
CN101781348A (en) | 2010-07-21 |
CN102250179B (en) | 2014-10-01 |
WO2011085701A1 (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2908332T3 (en) | Crystalline form of Ribosylnicotinamide chloride | |
CN102471248B (en) | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid | |
CN115403626A (en) | Novel crystalline forms | |
CN107428791A (en) | The crystal form of nicotinamide riboside | |
JPS5838421B2 (en) | Ornithine and arginine salts of branched keto acids and their use in the treatment of liver and kidney disorders | |
CN101633683B (en) | Antihepatitis medicament, preparation method thereof and use thereof | |
JPH02500373A (en) | Acyl deoxyribonucleoside derivatives and their uses | |
CN102250179B (en) | Stable protein kinase activator, and preparation method and purpose thereof | |
CN107921061A (en) | The amorphous calcium carbonate stablized with polyphosphoric acid/polyphosphate/Quadrafos or two banks/bisphosphonate/diphosphonate | |
CN106916177A (en) | A kind of deuterated dipeptide boronic acid or its ester type compound and its synthetic method and purposes | |
CN101172112A (en) | Compound with special property, composition containing the compound, preparing method and uses of the same | |
CN111635309A (en) | Novel antipyretic analgesic drug and preparation method and application thereof | |
CN104628796A (en) | Gastrodin medicine, and composition and use thereof | |
BR122021004504B1 (en) | USE OF AN ANTIMICROBIAL COMPOUND | |
CN104434819A (en) | Aceglutamide powder injection medicine composition for injection and preparation method of medicine composition | |
WO2021139797A1 (en) | Entrectinib crystal form and preparation method therefor | |
CN110183504B (en) | Gemcitabine prodrug with tumor targeting function and preparation method and application thereof | |
US20090275654A1 (en) | Pharmaceutical Gallium Compositions and Methods | |
FI92391C (en) | Process for the preparation of 3- (N-phenylacetylaminopiperidine) -2,6-dione | |
CN102351881B (en) | Stable levofloxacin hydrochloride compound | |
RU2428414C2 (en) | Method of producing creatine amides | |
CN101514189B (en) | Glycin diazole tromethamine compound as well as preparation method and medicament application thereof | |
JPS5810377B2 (en) | Encaridino - Calcium Noseizouhouhou | |
CN103012421B (en) | Iloquinoline derivative medicine and preparation thereof and purposes | |
CN102002050B (en) | Bisbenzylisoquinoline derivative and preparation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111123 Assignee: Datong Wuzhou Pharmaceutical Co.,Ltd. Assignor: Liu Li Contract record no.: 2015420000004 Denomination of invention: Stable protein kinase activator, and preparation method and purpose thereof Granted publication date: 20141001 License type: Common License Record date: 20150106 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141001 |